Shots:

• The GALAD score combines gender and age with the biomarker results of the Elecsys AFP- AFP-L3 and PIVKA-II and is intended to aid diagnosis of early-stage HCC
• The Elecsys GALAD will be the first GALAD score with regulatory approval to be used as IVD targeting the improvement in diagnostic workflows in the management of chronic liver disease
• The Elecsys GALAD score in combination with blood-based biomarkers support clinicians by providing them accurate and timely information to make earlier interventions- thus improves patient’s outcomes and reduces the mortality rate in patients with HCC

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche